Table 2 summarizes the differences between Group A (≥12% ALP+ blasts cells) and Group B (<12% ALP+ blasts cells) adjusted for the age, sex, type of AML (de novo or secondary), WHO Classification of AML (2017 edition), cytogenetic and molecular alterations, prognostic-risk group based on cytogenetic and molecular profile, relevant blast immunophenotyping (CD34/CD117/CD123 backbone), post-remission therapy, and outcomes (complete response achievement, relapse or treatment resistance, and exitus). This evidence concerns the gene CD34 and acute myeloid leukemia.